ALLOPHARM.BE: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ALLOPHARM.BE
Largest movements
- Receivables within one year -€9,637
down €9,637 (-98.2%), from €9,818 to €181
of which Trade receivables: -€9,739
- Stocks and contracts -€2,769
down €2,769 (-28.3%), from €9,780 to €7,011
- Cash +€1,118
up €1,118 (+13.5%), from €8,268 to €9,386
mainly Receivables within one year (+€9,637) and Stocks and contracts (+€2,769)
- Deferred charges and accrued income +€652
up €652 (+137%), from €475 to €1,127
- Other debts -€9,322
down €9,322 (-16.6%), from €56,176 to €46,854
- Trade debts -€2,957
down €2,957 (-32.3%), from €9,160 to €6,202
- Profit (loss) carried forward +€1,730
up €1,730 (+0.6%), from -€308,668 to -€306,938
- Gross operating margin -€3,731
down €3,731 (-38.7%), from €9,632 to €5,901
- Financial charges +€2,361
up €2,361 (+614%), from €384 to €2,746
- Depreciation -€580
down €580 (-28.9%), from €2,005 to €1,425
- Other operating charges -€100
no longer reported in 2025 (was €100)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €30,529 | €19,980 | -€10,549 | -34.6% |
| Fixed assets | 21/28 | €2,188 | €2,275 | +€88 | +4.0% |
| Tangible fixed assets | 22/27 | €2,188 | €2,275 | +€88 | +4.0% |
| Furniture and vehicles | 24 | €2,188 | €2,275 | +€88 | +4.0% |
| Current assets | 29/58 | €28,341 | €17,704 | -€10,637 | -37.5% |
| Stocks and contracts in progress | 3 | €9,780 | €7,011 | -€2,769 | -28.3% |
| Stocks | 30/36 | €9,780 | €7,011 | -€2,769 | -28.3% |
| Amounts receivable within one year | 40/41 | €9,818 | €181 | -€9,637 | -98.2% |
| Trade receivables | 40 | €9,739 | - | -€9,739 | |
| Other amounts receivable | 41 | €79 | €181 | +€102 | +130% |
| Cash at bank and in hand | 54/58 | €8,268 | €9,386 | +€1,118 | +13.5% |
| Deferred charges and accrued income | 490/1 | €475 | €1,127 | +€652 | +137% |
| Total equity and liabilities | 10/49 | €30,529 | €19,980 | -€10,549 | -34.6% |
| Equity | 10/15 | -€34,806 | -€33,076 | +€1,730 | +5.0% |
| Contributions | 10/11 | €273,862 | €273,862 | = | 0.0% |
| Capital | 10 | €273,862 | €273,862 | = | 0.0% |
| Issued capital | 100 | €273,862 | €273,862 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€308,668 | -€306,938 | +€1,730 | +0.6% |
| Amounts payable | 17/49 | €65,335 | €53,056 | -€12,279 | -18.8% |
| Amounts payable within one year | 42/48 | €65,335 | €53,056 | -€12,279 | -18.8% |
| Trade debts | 44 | €9,160 | €6,202 | -€2,957 | -32.3% |
| Suppliers | 440/4 | €9,160 | €6,202 | -€2,957 | -32.3% |
| Other amounts payable | 47/48 | €56,176 | €46,854 | -€9,322 | -16.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,005 | €1,425 | -€580 | -28.9% |
| Other operating charges | 640/8 | €100 | - | -€100 | |
| Gross operating margin | 9900 | €9,632 | €5,901 | -€3,731 | -38.7% |
| Operating profit (loss) | 9901 | €7,527 | €4,476 | -€3,051 | -40.5% |
| Financial charges | 65/66B | €384 | €2,746 | +€2,361 | +614% |
| Recurring financial charges | 65 | €384 | €2,746 | +€2,361 | +614% |
| Profit (loss) for the period before taxes | 9903 | €7,143 | €1,730 | -€5,412 | -75.8% |
| Profit (loss) for the period | 9904 | €7,143 | €1,730 | -€5,412 | -75.8% |
| Profit (loss) for the period to be appropriated | 9905 | €7,143 | €1,730 | -€5,412 | -75.8% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 16 October 2026 via checked.be.